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ABSTRACT 
The life-threatening mycoses caused by opportunistic fungal pathogens (mainly species 
from the genus Candida) associated with nosocomial infections, are one of the major 
health problems in our days. Therefore, it is crucial to identify new compounds, 
especially natural ones, that are active against the most broaden spectrum of Candida 
species. Herein, a screening of the antifungal potential of a phenolic extract of Cistus 
ladanifer from Northeastern Portugal, against Candida species was performed. 
Furthermore, the extract was characterized by HPLC-DAD-ESI/MS. Phenolic acids and 
derivatives (3.96 mg/g extract), ellagic acid derivatives (30.34 mg/g extract), and 
flavonoids (4.15 mg/g extract), such as catechins, flavonols and flavones, were found in 
the sample. The most abundant group was ellagic acid derivatives in which punicalagin 
gallate, a derivative of punicalagin attached to gallic acid, was found in highest amount 
(15.99 ± 0.02 mg/g extract). These compounds (i.e., ellagitannins) could be related to 
the strong inhibition of C. albicans, C. glabrata and C. parapsilosis growth (MIC < 
0.05 mg/ml). Moreover, the best antifungal activity was against C. glabrata, where the 
studied extract was able to cause at least 3 Log of reduction at concentrations below 
0.05 mg/mL and a total growth inhibition at concentrations above 0.625 mg/mL.  
 
Keywords: Cistus ladanifer; phenolic compounds; HPLC-DAD-ESI/MS; Candida 
species, antifungal activity 
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1. Introduction  
Nosocomial infections are one of the major health problems in our days, being the life-
threatening mycoses caused by opportunistic fungal pathogens associated with those 
infections, and the most prevalent species from the genus Candida (Calderone, 2002; 
Lass-Flör, 2009). In clinical practice, the most commonly encountered member of the 
genus is Candida albicans. However, several non-Candida albicans Candida (NCAC) 
spp, such as C. tropicalis, C. parapsilosis, and C. glabrata, have been increasingly 
implicated in human disease (Costa et al., 2010; Martins et al., 2010). This increased 
incidence can be attributed to improved identification methods but can also be a 
reflection of the high level of resistance often exhibited by NCAC species to antifungal 
agents (González et al., 2008; Negri et al., 2009).  
It has been reported the antimicrobial activity of several plants, related to their phenolic 
compounds (Rauha et al., 2000; Erasto et al., 2004; Tepe et al., 2004),  including the 
antibacterial activity of Cistus ladanifer L. aqueous extracts containing ellagitannins 
(Barrajón-Catalán et al., 2010). This aromatic plant is a Mediterranean shrub from the 
Cistaceae family, having white flowers and viscid stems and leaves producing a fragrant 
oleoresin used in perfumes especially as a fixative. It is widely distributed in Portugal, 
being one of the most abundant species in the southern part of the country, occurring in 
large areas as pure dense stands (Teixeira et al., 2007). Cistus ladanifer and other 
species of Cistaceae are used as general remedies in folk medicine for treatment of 
various skin diseases, as antidiarrheics, and as anti-inflammatory agents (Attaguile et 
al., 2000). 
As far as we know there are no reports on antifungal activity of the mentioned plant and 
the reports on phenolic composition refers to samples from Spain (Fernández-Arroyo et 
al., 2010; Barrajón-Catalán et al., 2010; Barrajón-Catalán et al., 2011). Herein, a 
screening of the antifungal potential of phenolic extracts of Cistus ladanifer against 
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Candida species was performed, and the extracts were further characterized by HPLC-
DAD-ESI/MS. 
 
2. Materials and methods 
 
2.1. Samples 
Cistus ladanifer fresh leaves from flowering steams were collected randomly, from wild 
plants growing in the Natural Park of Montesinho (Northeastern Portugal) in July 2008.  
Morphological key characters from the Flora Iberica were used for plant identification: 
Cistus ladanifer (Castroviejo, 2005). Voucher specimens from each plant were 
numbered and deposited in the Herbarium of the ESA. The vegetal material was 
lyophilized (Ly-8-FM-ULE, Snijders, Netherlands) and stored in the deep-freezer at -20 
ºC for subsequent analysis. 
 
2.2. Standards and reagents 
HPLC-grade acetonitrile was obtained from Merck KgaA (Darmstadt, Germany). 
Formic and acetic acids were purchased from Prolabo (VWR International, France). The 
phenolic compounds standards (apigenin-6-C-glucoside, catechin, ellagic acid, gallic 
acid, kaempferol-7-O-neohesperidoside, quercetin-3-O-glucoside, vanillic acid) were 
from Extrasynthese (Genay, France). RPMI 1640 medium was from Sigma (St. Louis, 
MO). Water was treated in a Milli-Q water purification system (TGI Pure Water 
Systems, USA). 
 
2.3. Preparation of the phenolic extracts 
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The sample (1 g) was extracted with 30 mL of methanol:water 80:20 (v/v) at room 
temperature, 150 rpm, for 1h. The extract was filtered through Whatman nº 4 paper, and 
the residue was re-extracted twice. The combined extracts were evaporated at 35 ºC 
(rotary evaporator Büchi R-210) to remove methanol. The aqueous phase was 
lyophilized and re-dissolved in a) 20% aqueous methanol at 5 mg/mL and filtered 
through a 0.22-µm disposable LC filter disk for High Performance Liquid 
Chromatography (HPLC) analysis, or b) distilled water at 200 mg/mL for antifungal 
assays. 
 
2.4. Phenolic compounds identification and quantification 
The extracts were analysed using a Hewlett-Packard 1100 chromatograph (Agilent 
Technologies) with a quaternary pump and a diode array detector (DAD) coupled to an 
HP Chem Station (rev. A.05.04) data-processing station. A Waters Spherisorb S3 ODS-
2 C18, 3 µm (4.6 mm × 150 mm) column thermostatted at 25 °C was used. The solvents 
used were: (A) 2.5% acetic acid in water, (B) 2.5% acetic acid/acetonitrile (90:10, v/v) 
and (C) HPLC-grade acetonitrile. The elution gradient established was 0% to 100% B 
for 5 min, from 0 to 5% C for 35 min, from 5 to 50 % C for 5 min, isocratic 50% C for 5 
min, and re-equilibration of the column, using a flow rate of 0.5 mL/min. Double online 
detection was carried out in the DAD using 280 nm and 370 nm as preferred 
wavelengths and in a mass spectrometer (MS) connected to HPLC system via the DAD 
cell outlet. 
MS detection was performed in an API 3200 Qtrap (Applied Biosystems, Darmstadt, 
Germany) equipped with an ESI source and a triple quadrupole-ion trap mass analyzer 
that was controlled by the Analyst 5.1 software. Zero grade air served as the nebulizer 
gas (30 psi) and turbo gas for solvent drying (400 ºC, 40 psi). Nitrogen served as the 
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curtain (10 psi) and collision gas (medium). The quadrupols were set at unit resolution. 
The ion spray voltage was set at -4000V in the negative mode. The MS detector was 
programmed for recording in two consecutive modes: Enhanced MS (EMS) and 
enhanced product ion (EPI) analysis. EMS was employed to achieve a full scan spectra, 
allowing an overview of all the ions present in sample. Settings used were: declustering 
potential (DP) -40 V, entrance potential (EP) -7 V, collision energy (CE) -20V. EPI 
mode was performed in order to obtain the fragmentation pattern of the parent ion(s) in 
the previous scan using the following parameters: DP -40 V, EP -10 V, CE -25V, and 
collision energy spread (CES) 0 V. Spectra were recorded in negative ion mode between 
m/z 100 and 1400. 
The phenolic compounds present in the samples were characterised according to their 
UV and mass spectra and retention times compared with commercial standards when 
available. For the quantitative analysis of phenolic compounds, a calibration curve was 
obtained by injection of known concentrations (1-100 µg/ml) of different standards 
compounds: apigenin-6-C-glucoside (y=517.4x+268.26; R2=0.9921); catechin  
(y=161.23x+177.26; R2=0.9992); ellagic acid (y=36.81x+257.13; R2=0.9979); gallic 
acid (y=298.26x–634.14; R2=0.9949); kaempferol-7-O-neohesperidoside 
(y=279.99x+404.53; R2=0.9902); quercetin-3-O-glucoside (y=363.45x+117.86; 
R2=0.9994); vanillic acid (y=364.98x+603.85; R2=0.9985). The results were expressed 
in mg per g of extract, as mean ± standard deviation of three independent analyses. 
 
2.5. Antifungal activity 
Four reference strains from the American Type Culture Collection (ATCC), namely 
Candida albicans (ATCC 90028), Candida tropicalis (ATCC 750), Candida glabrata 
(ATCC 2001) and Candida parapsilosis (ATCC 22019) were used. Before each 
7 
 
experiment, all reference species were grown on Sabouraud Dextrose Agar (SDA; 
Merck, Germany) for 24 h at 37 ºC. Yeast cells from at least five colonies (1 mm 
diameter) were suspended in 5 mL of sterile saline solution (0.85%) and the resulting 
yeast suspension was mixed for 15 s in a vortex. Then, the suspensions were adjusted by 
spectrophotometric method, adding saline solution to reach the value of 0.5 in the 
McFarland scale corresponding to a final concentration of 3.0 ± 2.0 × 106 cells/mL. The 
minimal inhibitory concentration (MIC) was determined according with the guidelines 
from the National Committee for Clinical Laboratory Standards (NCCLS), M27-A2 
document (NCCLS, 2002) with some modifications. Briefly, serial dilutions of plant 
extract stock solutions were prepared in RPMI 1640 medium (Sigma, St Louis, MO), 
buffered to pH 7 and ranging from 0.05 to 5 mg/ml.  Aliquots of the extract (100 µL), at 
a twofold final concentration, and Candida species suspensions (100 µL) were mixed in 
the 96-well plates (Orange Scientific, Braine-l’ Alleud, Belgium). The MIC values and 
the colony forming units (CFUs) were determined after 48 hours of incubation at 37 ºC. 
Drug-free and yeast controls were also included.  
 
3. Results and discussion 
The difficulties associated with the management of Candida infections have been 
increasing during the last decades due to their low susceptibility to the available 
antifungal therapies (Ruhnke, 2006; Naeini et al., 2009). Thus, in order to overcome this 
problem it is of major importance to identify new compounds, especially natural ones, 
that are active against the most broaden spectrum of Candida species. Herein, phenolic 
extracts from C. ladanifer were explored as a source of antifungal agents. The phenolic 
composition of the sample was characterized as containing phenolic acids and 
derivatives, ellagic acid derivatives and flavonoids (Figure 1 and Table 1).  
8 
 
Among phenolic acids and derivatives, peaks 1, 2 and 6 were determined as galloyl 
glucose isomers, presenting a pseudomolecular ion [M-H]- at m/z 331 that released an 
MS2 fragment at m/z 169 ([M-162]-, loss of a hexose moiety) corresponding to gallic 
acid. Similarly, peak 7 was characterized as digalloyl-glucose. Peak 5 presented a 
pseudomolecular ion [M-H]- at m/z 315 releasing a unique MS2 fragment at m/z 153 
([M-162]-) and was assigned to gentisoyl glucoside, based on a previous identification 
by Fernández-Arroyo et al. (2010). Peaks 9 and 24 corresponded to vanillic and ellagic 
acids, respectively, identified by comparison of their UV and mass spectra and retention 
time with commercial standards. 
Various peaks were identified as ellagitannins. Peaks 10 and 12 were assigned to 
punicalagin isomers according to their pseudomolecular ion ([M-H]- at m/z 1083) and 
fragmentation pattern as described by Seeram et al. (2005) and Fernández-Arroyo et al. 
(2010). Similarly, peaks 3 and 4 ([M-H]- at m/z 781) were identified as punicalin 
isomers (Seeram et al., 2005), and peak 14 ([M-H]- at m/z 1085) as cornusiin B, already 
described in C. ladanifer by Fernández-Arroyo et al. (2010).  Peaks 11 and 15 ([M-H]- 
at m/z 1251) were tentatively identified as derivatives of punicalagin attached to gallic 
acid, previously reported in Cistus species by Saracini et al. (2005). In this case the 
gallic acid would not be bound to punicalagin by the carboxyl group, as denoted by the 
fragment at m/z 1083 corresponding to the loss of gallic acid itself. These compounds 
were not identified in the sample of C. ladanifer analyzed by Fernández-Arroyo et al. 
(2010). 
Considering flavonoids, peaks 8 and 13 showed λmax at 274 nm characteristic of 
prodelphinidins with a pseudomolecular ion [M-H]- at m/z 305, were identified as 
gallocatechin and epigallocatechin (flavan-3-ols) by comparison with our data library.  
Peaks 18, 19, 21, 22 and 23 were identified as quercetin derivatives (λmax around 350-
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360 nm, and MS2 fragment at m/z 301). Peak 22 ([M-H]- at m/z 463) was positively 
identified as quercetin-3-O-glucoside by comparison with a commercial standard. Peak 
23 ([M-H]- at m/z 433) was associated to a quercetin-O-pentoside, and peaks 18 and 21 
([M-H]- at m/z 595) to quercetin-O-hexoside-pentosides, in which the sugar moieties 
constituted a disaccharide as deduced from the release of a unique MS2 fragment. Peak 
19 presented a pseudomolecular ion [M-H]- at m/z 625, showing two fragments at m/z 
463 and 301 corresponding to the losses of one and two a hexosyl residue, respectively, 
which allowed identifying it as a quercetin-O-hexoside-O-hexoside (sugars located at 
different positions on quercetin). 
Peaks 20 and 26 corresponded to kaempferol derivatives (λmax around 334 nm, and MS2 
fragment at m/z 285). Peak 20 ([M-H]- at m/z 609) was characterised as kaempferol-O-
hexoside-O-hexoside based on its fragmentation pattern similar to peak 19. Peak 26 
presented a pseudomolecular ion [M-H]- at m/z 593 that released fragments at m/z 447 
([M-H-146]-, loss of a rhamnosyl moiety) and 285 ([M-H-146-162]-, loss of a hexosyl 
moiety). The fact that no fragment resulting from the exclusive loss of hexosyl residue 
pointed to that the rhamnose was not directly to the aglycone but the two glycosyl 
moieties are constituting a disaccharide. Indeed, this fragmentation pattern is 
characteristic of flavonoid rutinosides, in which the 1-6 linkage between rhamnose and 
glucose allows for free rotation being more accessible to fragmentation than other 
disaccharides (Giusti et al., 1999). Therefore, the peak was tentatively identified as a 
kaempferol-O-rutinoside.  
Peak 25 presented a pseudomolecular ion [M-H]- at m/z 475 releasing a fragment at m/z 
313 ([M-H-162]- coherent with a kaempferol dimethylether aglycone, which was 
identified by Fernandez-Arroyo et al. (2010) in a sample of C. ladanifer. Thus, the 
compound was assigned to a kaempferol-dimethylether hexoside. A peak with a 
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pseudomolecular ion [M-H]- at m/z 475 was also detected by those authors in C. 
ladanifer although they did not offer any tentative identity. Peak 27 ([M-H]- at m/z 299) 
was identified as a methylether of kaempferol based on the production of a major MS2 
fragment at m/z 285 ([M-H-14]-, loss of a methyl residue). 
Peak 17 showed a pseudomolecular ion [M-H]- at m/z 593 that released three MS2 
fragments ions at m/z 473 and 383, corresponding to loss of 120 and 90 amu, 
characteristic of C-hexosyl flavones, and at m/z 353 that might correspond to an 
apigenin aglycone bearing some sugar residues [apigenin + 83 mu] that remained linked 
to it (Ferreres et al., 2003). A compound with similar mass characteristics was found by 
Barrajón-Catalán et al. (2011) in C. ladanifer and associated to a diglycosylated 
apigenin. Since the two hexosyl residues are C-attached, it might be tentatively 
identified as apigenin-6-C-glucose-8-C-glucose.  
Finally, peak 16 ([M-H]- at m/z 327) was assigned to 3,4´-dihydroxypropiophenone-3-β-
D-glucoside as previously reported in C. ladanifer by Fernandez-Arroyo et al. (2010).  
Herein, it was found a similar profile to the ones reported by Fernandez-Arroyo et al. 
(2010) and Barrajón-Catalán et al. (2010; 2011) in aqueous extracts of Spanish C. 
ladanifer samples. Nevertheless, some compounds reported by those authors (digalloyl-
β-D-glucopiranose, pedunculagin, uralenneoside, strictinin, mirciaphenone B, ellagic 
acid-7-xyloside, ducheside A, apigenin and apigenin methylether) were not detected in 
our sample, which in turns contained others (punicalagin gallate, quercetin-O-hexoside-
O-pentoside, quercetin-O-pentoside and kaempferol-O-rhamnoside-O-hexoside) that 
were not cited in the Spanish samples.  
Fernandez-Arroyo et al. (2010) and Barrajón-Catalán et al. (2011) did not perform the 
quantification of individual compounds, so it is not possible to compare quantities found 
in both samples. Barrajón-Catalán et al. (2011) performed only the quantification of 
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four compounds and expressed the results as percentages (0.242% ± 0.004 (w/w) of 
gallic acid, and 3.50% ± 0.02 for the sum of three ellagitannins including punicalin and 
punicalagin), being also difficult the comparison of the results. The sample studied 
herein presented a total amount of phenolic compounds of 38.44 mg/g extract, 
distributed in phenolic acids and derivatives (3.96 mg/g), ellagic acid derivatives (30.34 
mg/g) and flavonoids (4.15 mg/g). The most abundant group was ellagic acid 
derivatives in which punicalagin gallates (peaks 11 and 15, 7.89 ± 0.29 and 8.10 ± 0.31 
mg/g extract, respectively) were the compounds found in highest amount. 
The in vitro activity of the studied C. ladanifer extract against four Candida species was 
evaluated. Aligiannis et al. (2001) proposed a classification for plant extracts effect 
against Candida species based on MIC values obtained in: strong inhibitors (MIC up to 
0.5 mg/mL), moderate inhibitors (MIC between 0.6 and 1.5 mg/mL), and weak 
inhibitors (MIC above 1.6 mg/mL). According to that distribution, the phenolic extract 
of C. ladanifer would act as a strong inhibitor of C. albicans, C. glabrata and C. 
parapsilosis growth (MIC < 0.05 mg/mL), and as a moderate inhibitor of C. tropicalis 
growth (MIC = 0.625 mg/mL). Bruni et al. (2003) also demonstrated that C. albicans 
ATCC 48274 was markedly inhibited by oils rich in phenolics, aldehydes and alcohols.  
The results of chemical characterization (Table 1) shows that the studied C. ladanifer 
extract was mostly constituted by phenolic compounds, which would thus explain its 
antifungal activity caused by C. ladanifer extract against the Candida species under 
study.  
The number of viable Candida, determined by CFU enumeration, was determined using 
different concentration of C. ladanifer extract (Figure 2), showing that the activity of 
this latter varied with the species. Specifically, the highest antifungal activity was 
against C. glabrata, where this extract was able to cause at least 3 Log of reduction at 
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concentrations below 0.05 mg/mL, and a total growth inhibition at concentrations above 
0.625 mg/mL. In the case of C. albicans and C. tropicalis, complete growth inhibition 
was only observed for the highest assayed concentration (5 mg/mL), indicating less 
susceptible of these species to C. ladanifer extract than C. glabrata.  Nonetheless, the 
extract was able to cause a reduction of approximately 3 Log in C. albicans and C. 
tropicalis at concentrations above 0.155 mg/mL. None of the extract concentrations 
tested was able to reduce completely the C. parapsilosis growth. This was very 
interesting considering the low MIC value (0.05 mg/mL) obtained for this species, 
indicating that even though its growth was impaired at 0.05 mg/mL, in fact, cells were 
still viable. 
No results concerning antifungal activity have been found in the literature for phenolic 
extracts of C. ladanifer. Barrajón-Catalán et al. (2010) reported antimicrobial activity 
against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) 
bacteria of C. ladanifer aqueous extract that was more active against Gram-positive 
bacteria.  
Overall, the phenolic extract of C. ladanifer affected the growth of different Candida 
sp., suggesting that the compounds present in the extract could play an active role in the 
protection against fungi related to several diseases. Future work will include the 
evaluation of antifungal activity of those compounds (isolated from the plant or 
commercial compounds when available).  
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Table 1. Retention time (Rt), wavelengths of maximum absorption in the UV-vis region (λmax), pseudomolecular and MS2 fragment ions (in 
brackets, relative abundances), tentative identification and quantification of the phenolic compounds in the studied C. ladanifer extract.  
Peak Rt (min) 
λmax 
 (nm) 
Pseudomolecular ion 
[M-H]- (m/z) 
MS2 
(m/z) 
Tentative identification 
Quantificationa  
(mg/g, extract) 
1 7.74 280 331 331(100), 169(14), 125(33) Galloyl glucose 0.76 ± 0.02 
2 8.80 270 331  331(33), 169(100), 125(37) Galloyl glucose 1.35 ± 0.09 
3 9.4 260,380 781 781(100), 721(7), 601(23), 299(10)  Punicalin isomer 1 0.07 ± 0.01 
4 9.78 260, 381 781 781(100), 721(7), 601(35), 299(15)  Punicalin isomer 2 0.32 ± 0.07 
5 10.29 260, 312 315 153(91), 109(27)  Gentisoyl hexoside nq 
6 10.75 278 331 169(100), 125(63) Galloyl glucose 0.87 ± 0.05 
7 11.21 243, sh297, 339 483 331(40), 169(100), 125(23) Digalloyl glucose 0.78 ± 0.05 
8 11.63 273 305 219(45), 179(41), 125(100)  Gallocatechin 0.48 ± 0.05 
9 11.90 252, 290 167 152(100), 123(15) Vanillic acid 0.05 ± 0.01 
10 12.61 258, 380 1083 781(17), 601(16), 301(100) Punicalagin isomer 1 5.90 ± 0.15 
11 14.65 259, 378 1251 1083(4), 781(13), 601(4), 301(13) Punicalagin gallate 1 7.89 ± 0.29 
12 16.17 260, 379 1083 781(12), 601(25), 301(93) Punicalagin isomer 2 7.90 ± 0.19 
13 17.42 274 305 219(33), 179(33), 125(100)  Epigallocatechin 1.59 ± 0.21 
14 19.65 240,378 1085 783(10), 542(44), 451(46), 301(100) Cornusiin B 0.15 ± 0.02 
15 21.34 258, 380 1251 1083(6), 781(4), 601(19), 301(33) Punicalagin gallate 2 8.10 ± 0.31 
16 29.38 276 327 327(59), 165(100) 3,4´-Dihydroxypropiophenone-3-β-D-glucoside nq 
17 34.53 338 593 473(30), 383(31), 353(66) Apigenin-6-C-glucose-8-C-glucose 0.53 ± 0.01 
18 40.24 348 595 301(100) Quercetin-O-hexoside-O-pentoside 0.26 ± 0.00 
19 45.01 348 625 463(84), 301(100) Quercetin-O-hexoside-O-hexoside 0.40 ± 0.02 
20 47.83 334 609 447(29), 285(58) Kaempferol-O-hexoside-O-hexoside 0.06 ± 0.00 
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nq - not quantified; aThe results were expressed in mg per g of extract, as mean ± standard deviation of three independent analyses. 
  
21 51.51 356 595 301(100) Quercetin-O-hexoside-O-pentoside 0.08 ± 0.01 
22 52.29 360 463 301(100) Quercetin-3-O-glucoside 0.14 ± 0.00 
23 52.38 354 433 301(100) Quercetin-O-pentoside 0.16 ± 0.00 
24 53.19 294, 358 301 256(6), 185(15) Ellagic acid 0.15 ± 0.02 
25 53.28 334 475 313(100) Kaempferol dimethylether hexoside 0.06 ± 0.00 
26 54.24 334 593 447(8), 285(100) Kaempferol-O-rutinoside 0.06 ± 0.00 
27 56.45 350 299 285(100), 255(57), 227(29) Kaempferol methylether 0.32 ± 0.02 
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Figure 1. HPLC chromatogram of the C. ladanifer extract, recorded at 280 nm.  
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 Figure 2. Logarithm of number cells of C. albicans, C. glabrata, C. parapsilosis and C. 
tropicalis, grown in the presence of different concentrations of C. ladanifer phenolic 
extract, in SDB after 48 h. Error bars represent standard deviation. 
